ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
Regulatory Role of IGF2BP2 in Intestinal Mucosal Barrier Dysfunction in Ulcerative Colitis.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting TARDBP to Restore Colonic Barrier Integrity in Ulcerative Colitis via NFATC1 mRNA Destabilization.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: Ulcerative colitis (UC), an idiopathic and chronic inflammatory disease, primarily targets the mucosal lining of the colon. This research endeavors to reveal the mechanism of insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) and nuclear receptor coactivator-3 (NCOA3) in UC-induced intestinal mucosal barrier dysfunction. Materials and Methods: Dextran sodium sulfate (DSS) was used for UC mouse modeling, followed by an assessment of the disease activity index, intestinal barrier integrity, and intestinal permeability assessment through FITC-glucan assay. microRNA (miR)-222-3p, IGF2BP2, and NCOA3 levels in colon tissues of mice were detected. The targeted binding of miR-222-3p to IGF2BP2 was determined using a dual-luciferase assay. The enrichment of IGF2BP2 or N6-methyladenosine (m6A) on NCOA3 mRNA in YAMC cells was tested by RNA immunoprecipitation and m6A RNA immunoprecipitation assays, and the mRNA stability of NCOA3 was determined after actinomycin D treatment. Results: miR-222-3p was increased while IGF2BP2 and NCOA3 were decreased in the colon tissues of UC mice. IGF2BP2 overexpression effectively alleviated intestinal injury and reinstated the functional integrity of the mucosal barrier in DSS mice. IGF2BP2 recognized and bound to the m6A site of NCOA3 and increased mRNA stability, and miR-222-3p negatively regulated IGF2BP2. NCOA3 downregulation abated the beneficial impact of IGF2BP2 overexpression on DSS mice. miR-222-3p downregulation upregulated IGF2BP2/NCOA3 expression to protect against intestinal mucosal barrier dysfunction. Conclusion: IGF2BP2 was repressed by miR-222-3p, yet IGF2BP2 increased the stability of NCOA3 mRNA via an m6A-dependent pathway, ultimately leading to attenuation of UC-related intestinal mucosal barrier impairment and UC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.